Thursday, 26 April 2018 - 4:59
  • it
  • de
  • en
  • fr

Asthma

AstraZeneca’s asthma therapy approved in Europe as well

MedImmune’s (AstraZeneca) monoclonal antibody benralizumab has been approved in Europe for the treatment of severe asthma. The drug was recommended by EMA CHMP last November and was approved in the US in the same month. Benralizumab will be available as…

Significant news from AstraZeneca

AstraZeneca has reported results from the Phase III STRATOS 2 clinical trial, designed to assess tralokinumab, an anti-interleukin-13 (IL-13) monoclonal antibody in patients with uncontrolled asthma. The data show that tralokinumab does not provide any advantage on conventional therapies. Denmark-based…

FDA approves two products by Teva for asthma treatment

Teva Pharmaceutical announced that FDA has approved two products for adolescent and adult patients with asthma – AirDuo RespiClick (fluticasone propionate and salmeterol inhalation powder) and ArmonAir RespiClick (fluticasone propionate inhalation powder). Both treatments use Teva’s RespiClick, a breath-activated device….

Chiesi focuses on M&A again: Atopix Therapeutics acquired for €75m

Chiesi Farmaceutici announced today that it has acquired UK-based Atopix Therapeutics Limited for €75m. A part of the amount is subject to the achievement of precise regulatory and commercial milestones—should these exceed the set targets, the company value could even…

New Novartis in-office diagnostic test for IgE

Novartis announced today the introduction of a novel diagnostic tool – the NijiTM System and Total IgE Test. The test delivers total IgE levels in about 12 minutes using a maximum of two droplets of finger stick blood, thus allowing…

Cochrane: Vitamin D may reduce the risk of asthma attacks

A Cochrane review, which took into consideration nine studies, found that taking vitamin D supplementation cuts the risk of severe asthma attacks. The trials were carried out in the United States, Canada, India, Japan, Poland and the United Kingdom. The…